Drugs / HXN5003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07549750 | May 2026 → Mar 2027 expected | atopic eczema | Helixon Biotechnology (Suzhou) Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HXN5003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07549750 ↗ |
| Route | Subcutaneous | “Subcutaneous injection (SC)” NCT07549750 ↗ |